London, 3 June 2015: Technavio, the independent tech-focused global research firm, has published a report on the asthma drugs market in the US 2015-2019, which is expected to grow at a CAGR of 4.64% during the forecast period of 2014-2019.
Market revenue for the asthma drugs market in the US is expected to increase owing to the introduction of pipeline products. These pipeline products conceal the decreasing market revenue, which is caused by the patent expiries of major drugs. The launch of promising late-stage pipeline products, like Benralizumab and Mepolizumab, enhance growth of this market as they have better safety and efficacy profiles than the presently available drugs.
“Patients with persistent asthma symptoms are treated with drugs for both symptomatic relief and as a preventive measure. This helps in the reduction of asthma flare-ups,” says Faisal Ghaus, Vice President of Technavio.
“Generally, a patient is prescribed long-acting beta-2 agonist (LABA) or leukotriene receptor antagonist (LTRA) along with inhaled corticosteroid (ICS). LABA and LTRA differ in their mechanisms of action but both provide complementary benefits in combination with an ICS.”
Key Market Drivers:
- High prevalence of asthma.
- Promising late-stage pipeline molecules.
- Expected launch of personalized medicine.
- Increased environmental pollution.
Key Market Trends:
- Growing popularity of combination therapies.
- High preference for biologics.
- Increased use of ICS/LABA once-daily therapies.
- Rise in awareness programs.
Key Market Vendors:
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
